Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIKNIC: Piqray in Advanced Breast Cancer
NCT02506556Phase 2Completed
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Sep 2015
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alpelisib in breast cancer, sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Objective Response Rate up to 60 months. Started Sep 2015; status: completed.
02
Drugs
alpelisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02506556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02506556.